Drug Trial Radar · NCT06809595
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
245
Actual
Start
Jan 29, 2025
Primary completion
Aug 13, 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Definium Therapeutics US, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Conditions
- Generalized Anxiety Disorder
Interventions
PlaceboOther
A substance that is designed to have no therapeutic value
DT120Drug
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12Time frame: Baseline to Week 12
Locations
36 sites in 6 countries. Site status is shown where the registry gives one.
Preferred Research Partners, Inc.
Little Rock, Arkansas
Psychedelic Science Institute
Los Angeles, California
West Los Angeles VA Medical Center
Los Angeles, California
Bradenton Research Center, Inc.
Bradenton, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
Sheppard Pratt Health System
Towson, Maryland
Adams Clinical Boston
Boston, Massachusetts
Princeton Medical Institute
Princeton, New Jersey
University of Cincinnati Psychiatry- Anxiety Disorders Research Program
Cincinnati, Ohio
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio
Austin Clinical Trial Partners
Austin, Texas
Core Clinical Research
Everett, Washington
A-shine s.r.o.
Pilsen, Czechia
Institut Neuropsychiatricke Pece (INEP)
Prague, Czechia
Psyon s.r.o.
Prague, Czechia
Cabinet Dr.Desbonnet : Résidence Saint Michel
Douai, France
Hôpital Conception, CIC Centre, bat néphrologie 3eme étage
Marseille, France
CMME
Paris, France
GHU Paris Psychiatrie et Neurosciences
Paris, France
Centre Hospitalier du Rouvray
Sotteville-lès-Rouen, France
Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin
Berlin, Germany
OVID Clinic Berlin
Berlin, Germany
Central Institute of Mental Health
Mannheim, Germany
Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie
Tübingen, Germany
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Poland
Department of Psychiatry, UCK
Gdansk, Poland
Department of Affective and Psychotic Disorders, Central Teaching Hospital, Medical University of Lodz
Lodz, Poland
Neuroclin Glasgow
Glasgow, United Kingdom
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St. Nicholas Hospital
Gosforth, United Kingdom
4 Medical Clinical Solutions
London, United Kingdom
Clerkenwell Health - Baker Street
London, United Kingdom
Clerkenwell Health
London, United Kingdom
South London and Maudsley NHS Foundation Trust of The Maudsley Hospital
London, United Kingdom
4 Medical Clinical Solutions
Manchester, United Kingdom
St George's Community Health Centre
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.